Zimmer Biomet — Aug 5, 2026 release

Importantly, we continue to advance our strategic priorities and remain confident our efforts will strengthen our business, build the boldest leader in MedTech, and better position Zimmer Biomet to deliver consistent, durable growth over the long term."   Recent Highlights • Announced increase to share repurchase expectations of up to $1 billion of its common stock during fiscal year 2026 . • Received U.S. FDA 510(k) clearance and completed first cases of the next generation ROSA ® Shoulder System , the first in the industry to support both glenoid and humeral bone preparation for anatomic and reverse techniques. • Recognized as “Best Healthcare Robotics Solution” in 2026 MedTech Breakthrough Awards ROSA ® Knee with OptimiZe ™ . • Named Chintan Desai president of the company's Asia Pacific Region to replace Sang Yi, who will depart the company on Aug. 28. • Named to TIME’s 2026 list of America’s Best Companies , demonstrating excellence across employee satisfaction, financial results and sustainability transparency. • Issued 2025 Sustainability Report , highlighting meaningful progress reducing the company’s environmental footprint, strengthening communities and expanding access to care. • Zimmer Biomet Institute held its inaugural Sharpening Your Edge immersive, hands-on bioskills training experience , designed to deliver immediate, practice-ready impact to early career surgeons.     Page 2 of 23   Geographic and Product Category Sales The following sales tables provide results by geography and product category for the three and six